MedTrace Logo

TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor

NCT04862767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-01-31

No results posted yet for this study

Summary

To evaluate safety, tolerance and efficacy of TASO(TGF-β2 targeting anti-sense oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced or metastatic solid tumor and to find appropriate dose for phase 2 clinical trial.

Conditions

Interventions

DRUG

TASO-001((TGF-β2 targeting anti-sense oligonucleotide)

96 hour continuous infusion

COMBINATION_PRODUCT

Aldesleukin

SC, Bid

Sponsors & Collaborators

  • Autotelicbio

    lead INDUSTRY

Principal Investigators

  • James Jun, M.D. · Autotelicbio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-09
Primary Completion
2023-08-21
Completion
2023-08-21

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04862767 on ClinicalTrials.gov